Default company panoramic image
Logo

Lung Therapeutics, Inc.

LTI leverages NIH validated and funded programs to develop first in class therapies for niche indications in lung injury and disease.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Austin, TX, USA
  • Currency USD

Company Summary

LTI pursues niche, orphan drug indications in lung injury and disease for which there is no effective therapeutic option. LTI’s first product, LTI-01 for pleural disease, has received more than $12 million dollars in NIH funding for development and IND-enabling studies, and it targets a global market worth over $1B.

Team

  • Default avatar
    Brian Windsor
    CEO

  • Default avatar
    Steven Idell
    CSO

  • Default avatar
    Andrew Mazar
    Head of Product Development

Previous Investors

  • Default avatar
    UT Horizon Fund
    Unconfirmed